

Cardiff Oncology Inc (CRDF) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/C0336C6141CDEN.html>

Date: September 2021

Pages: 55

Price: US\$ 125.00 (Single User License)

ID: C0336C6141CDEN

Abstracts

Cardiff Oncology Inc (CRDF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cardiff Oncology Inc (Cardiff Oncology), formerly Trovogene Inc is a clinical-stage biotechnology company that focuses on developing drugs which target cell division (mitosis) using precision cancer medicine (PCM) approach for the treatment of hematologic and solid tumor cancers. The company lead product candidate is Onvansertib (previously known as PCM-075), an oral and adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1) enzyme. It is being developed in combination with chemotherapies and targeted therapeutics for treatment of relapsed/refractory acute myeloid leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and second-line KRAS mutation-metastatic Colorectal Cancer (mCRC). Onvansertib is being evaluated in three clinical trials, namely, TROV-052, TROV-053, and TROV-054. Cardiff Oncology is headquartered in San Diego, California, the US.

Cardiff Oncology Inc Key Recent Developments

Aug 05,2021: Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates

Jul 12,2021: Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer

Jun 28,2021: Cardiff Oncology Added to the Russell 2000 and other FTSE Russell Indexes

Jun 10,2021: Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors

May 06,2021: Cardiff Oncology Announces First Quarter 2021 Results and Recent **Highlights**

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the

revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Cardiff Oncology Inc - Key Facts
Cardiff Oncology Inc - Key Employees
Cardiff Oncology Inc - Key Employee Biographies
Cardiff Oncology Inc - Major Products and Services
Cardiff Oncology Inc - History
Cardiff Oncology Inc - Company Statement
Cardiff Oncology Inc - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
Cardiff Oncology Inc - Business Description
Business Segment: Royalties
Performance
Business Segment: Service
Performance
Cardiff Oncology Inc - Corporate Strategy
Cardiff Oncology Inc - SWOT Analysis
SWOT Analysis - Overview
Cardiff Oncology Inc - Strengths
Cardiff Oncology Inc - Weaknesses
Cardiff Oncology Inc - Opportunities
Cardiff Oncology Inc - Threats
Cardiff Oncology Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cardiff Oncology Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 05, 2021: Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates

Jul 12, 2021: Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer

Jun 10, 2021: Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors

May 06, 2021: Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights

Mar 11, 2021: Cardiff Oncology to Present at the Oppenheimer 31st Annual Healthcare Conference

Mar 10, 2021: Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021

Mar 03, 2021: Cardiff Oncology to Present at H.C. Wainwright Global Life Sciences Conference

Feb 25, 2021: Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights

Feb 24, 2021: Cardiff Oncology to Participate in Gastrointestinal Oncology and Pancreatic Cancer Panel Discussion at the Cowen 41st Annual Health Care Conference

Dec 21, 2020: Cardiff Oncology announces the appointment of Dr. Rodney Markin as Chairman of the Board

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Cardiff Oncology Inc, Key Facts
Cardiff Oncology Inc, Key Employees
Cardiff Oncology Inc, Key Employee Biographies
Cardiff Oncology Inc, Major Products and Services
Cardiff Oncology Inc, History
Cardiff Oncology Inc, Key Competitors
Cardiff Oncology Inc, Ratios based on current share price
Cardiff Oncology Inc, Annual Ratios
Cardiff Oncology Inc, Annual Ratios (Cont...1)
Cardiff Oncology Inc, Interim Ratios
Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cardiff Oncology Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Cardiff Oncology Inc, Performance Chart (2016 - 2020)

Cardiff Oncology Inc, Ratio Charts

Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Cardiff Oncology Inc (CRDF) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/C0336C6141CDEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C0336C6141CDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970